Friday, October 2, 2009

Amicus says Gaucher drug misses goal in trial - Forbes


Amicus says Gaucher drug misses goal in trial
Forbes
Amicus shares fell $2.24, or 26 percent, to $6.26 in after-hours trading when the test results were released, following a gain of 17 cents, or 2 percent, ...

and more »
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)